» Articles » PMID: 30246360

Measurement Properties of Three Assessments of Burden Used in Atopic Dermatitis in Adults

Overview
Journal Br J Dermatol
Specialty Dermatology
Date 2018 Sep 25
PMID 30246360
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Standardized quality-of-life (QoL) assessments can provide important and clinically relevant information. There is currently a lack of standardization in QoL assessments used in atopic dermatitis (AD).

Objectives: To determine the content validity, construct validity, internal consistency, differential reporting, responsiveness, floor or ceiling effects and feasibility of the Dermatology Life Quality Index (DLQI), Itchy Quality of Life (ItchyQoL) and 5-dimensions (5-D) itch scales for assessing burden of AD in adults and to compare their performance.

Methods: Self-administered questionnaires and skin examination were performed in 340 adults with AD in a dermatology practice setting.

Results: DLQI, ItchyQoL and 5-D all had good content validity. DLQI, mean ItchyQoL and 5-D itch all had strong correlations with frequency of AD symptoms (Patient-Oriented Eczema Measure) and intensity of itch (numerical rating scale for itch), and moderate correlations with AD severity (Eczema Area and Severity Index and Scoring Atopic Dermatitis) (Spearman correlations, P < 0·001 for all). DLQI and 5-D itch showed good internal consistency (Cronbach's alpha = 0·89 and 0·84), although ItchyQoL appeared to have several redundant items (alpha = 0·96). Uniform and nonuniform differential item functioning by age, sex and/or race/ethnicity was found for multiple items in DLQI, ItchyQoL and 5-D itch. DLQI, ItchyQoL and 5-D itch scores all demonstrated responsiveness, although ItchyQoL demonstrated the greatest responsiveness. There were no floor or ceiling effects for total scores. The median times for completion of DLQI, ItchyQoL and 5-D itch were 2 min.

Conclusions: The DLQI, ItchyQoL and 5-D itch scales all showed good content and construct validity, and responsiveness in the assessment of AD in adults, and were feasible for use in clinical trials and practice.

Citing Articles

Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study.

Gooderham M, Guttman-Yassky E, Igawa K, Kabashima K, Esfandiari E, Rylands A Dermatol Ther (Heidelb). 2024; 14(12):3351-3366.

PMID: 39532780 PMC: 11604902. DOI: 10.1007/s13555-024-01303-z.


A Systematic Review of 207 Studies Describing Validation Aspects of the Dermatology Life Quality Index.

Vyas J, Johns J, Ali F, Ingram J, Salek S, Finlay A Acta Derm Venereol. 2024; 104:adv41120.

PMID: 39508500 PMC: 11559262. DOI: 10.2340/actadv.v104.41120.


The UPDATE trial (UVB Phototherapy in Dermatology for ATopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczema.

Knops E, Spuls P, Duijnhoven R, Dijkgraaf M, van Barreveld M, Arents B Trials. 2024; 25(1):482.

PMID: 39014498 PMC: 11253338. DOI: 10.1186/s13063-024-08334-z.


Correlation Analysis of Clinician- and Patient-Reported Outcomes Among Japanese Adults with Atopic Dermatitis.

Saeki H, Kataoka Y, Etoh T, Katoh N, Teramukai S, Tajima Y Dermatol Ther (Heidelb). 2024; 14(2):533-543.

PMID: 38326699 PMC: 10890985. DOI: 10.1007/s13555-023-01094-9.


Efficacy of Avène Hydrotherapy on Chronic Pruritus in Patients with Plaque Psoriasis.

Thouvenin M, Bacquey A, Babin M, Lestienne F, Lauze C, Gravier E Dermatol Ther (Heidelb). 2023; 13(12):3137-3151.

PMID: 37837493 PMC: 10689587. DOI: 10.1007/s13555-023-01047-2.


References
1.
Holm E, Esmann S, Jemec G . Does visible atopic dermatitis affect quality of life more in women than in men?. Gend Med. 2005; 1(2):125-30. DOI: 10.1016/s1550-8579(04)80017-2. View

2.
Hahn H, Melfi C, Chuang T, Lewis C, GONIN R, Hanna M . Use of the Dermatology Life Quality Index (DLQI) in a midwestern US urban clinic. J Am Acad Dermatol. 2001; 45(1):44-8. DOI: 10.1067/mjd.2001.110880. View

3.
Gerbens L, Prinsen C, Chalmers J, Drucker A, von Kobyletzki L, Limpens J . Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. Allergy. 2016; 72(1):146-163. DOI: 10.1111/all.12959. View

4.
Chren M, Lasek R, Quinn L, Mostow E, Zyzanski S . Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996; 107(5):707-13. DOI: 10.1111/1523-1747.ep12365600. View

5.
Simpson E, Bruin-Weller M, Flohr C, Ardern-Jones M, Barbarot S, Deleuran M . When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017; 77(4):623-633. DOI: 10.1016/j.jaad.2017.06.042. View